skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

Elanco to Acquire Bayer’s Animal Health Business in $7.6 Billion Deal

Paul, Weiss is representing Elanco Animal Health Incorporated (NYSE: ELAN) in its $7.6 billion cash-and-stock acquisition of the animal health business of Bayer AG, creating the world’s second-largest animal health business. The transaction is expected to close in mid-2020, pending customary conditions and regulatory approvals. Elanco, which spun out of Eli Lilly and Company earlier this year, is a global animal health company that develops and sells drugs and vaccines to prevent and treat diseases in farm animals and pets across more than 90 countries.

The team includes corporate partners Tarun Stewart, Ariel Deckelbaum, Thomas de la Bastide and David Huntington and counsel Caith Kushner; antitrust partners Andrew Forman and Rick Rule and counsel Marta Kelly; intellectual property counsel Jonathan Ashtor; tax partner Scott Sontag; litigation partners David Brown and Roberto Gonzalez and counsel Richard Elliot and Kripa Raman; employee benefits partner Andrew Gaines and counsel Jason Ertel; real estate partner Mitchell Berg; and environmental counsel William O’Brien.

Hengeler Mueller served as our German co-counsel and Slaughter and May as our European antitrust co-counsel.

August 20, 2019

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy